Chymotrypsin
drug drugOn this page
Also known as .alpha.-chymotrypsinAlpha chymarCataraseChymarChymoralChymoral fteChymotrypsineDeanase dcQuimotripsinaZolyseZonulysin
Summary
Chymotrypsin (CHEMBL1201465) is an approved unknown (ATC S01KX01); indicated across 1 condition including autism.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: S01KX01 (+1 more)
- Indications: 1 condition
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201465 |
| Name | Chymotrypsin |
| Type | Unknown |
| Max phase | 4 |
| ATC | S01KX01, B06AA04 |
Also known as: .alpha.-chymotrypsin, Alpha chymar, Catarase, Chymar, Chymoral, Chymoral fte, Chymotrypsin, Chymotrypsine, Deanase dc, Quimotripsina, Zolyse, Zonulysin
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| autism | 3 | MONDO:0005260 | EFO:0003758 |
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 1 |
| PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07506265 | PHASE4 | COMPLETED | Comparative Evaluation of Intraligamentary Injection of Dexamethasone, Diclofenac Sodium, and Chymotrypsin for Enhancing the Success of 4% Articaine Buccal Infiltration in Mandibular Molars With Symptomatic Irreversible Pulpitis |
| NCT07025408 | PHASE2 | RECRUITING | Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns |
| NCT06713733 | Not specified | RECRUITING | Comparison of Clinical Efficacy of Submucosal Dexamethasone and Oral Trypsin-chymotrypsin for Reduction of Postoperative Sequelae After Lower Third Molar Surgery |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: autism